Immuneering Corporation
IMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $317 | $2,080 |
| % Growth | – | -100% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $158 | $1,153 |
| Gross Profit | $0 | $0 | $159 | $927 |
| % Margin | – | – | 50.1% | 44.6% |
| R&D Expenses | $47,964 | $41,624 | $36,267 | $26,541 |
| G&A Expenses | $16,078 | $16,760 | $15,607 | $8,272 |
| SG&A Expenses | $16,078 | $16,760 | $15,607 | $8,272 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $29 | $29 | $30 | -$0 |
| Operating Expenses | $64,071 | $58,413 | $51,904 | $34,813 |
| Operating Income | -$64,071 | -$58,413 | -$51,745 | -$33,886 |
| % Margin | – | – | -16,325.8% | -1,629.2% |
| Other Income/Exp. Net | $3,035 | $4,941 | $1,231 | $43 |
| Pre-Tax Income | -$61,037 | -$53,472 | -$50,514 | -$33,843 |
| Tax Expense | $0 | $0 | $0 | -$307 |
| Net Income | -$61,037 | -$53,472 | -$50,514 | -$33,536 |
| % Margin | – | – | -15,937.3% | -1,612.3% |
| EPS | -2.04 | -1.88 | -1.87 | -1.27 |
| % Growth | -8.5% | -0.5% | -47.2% | – |
| EPS Diluted | -2.04 | -1.88 | -1.87 | -1.27 |
| Weighted Avg Shares Out | 29,982 | 28,417 | 26,387 | 26,320 |
| Weighted Avg Shares Out Dil | 29,982 | 28,417 | 26,387 | 26,320 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,593 | $3,607 | $1,014 | $170 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $385 | $352 | $277 | $159 |
| EBITDA | -$63,687 | -$58,061 | -$51,468 | -$33,727 |
| % Margin | – | – | -16,238.4% | -1,621.5% |